Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

NCT05141201

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Lupus Erythematosus, Systemic

Countries: Japan

To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

patients with systemic lupus erythematosus insufficiently responding to currently available treatment -

Exclusion Criteria:

None

\-
Locations (47)
  • Aichi, Japan
  • Akita, Japan
  • Aomori, Japan
  • Chiba, Japan
  • Ehime, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Fukushima, Japan
  • Gifu, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Hyōgo, Japan
  • Ibaraki, Japan
  • Ishikawa, Japan
  • Kagawa, Japan
  • Kagoshima, Japan
  • Kanagawa, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Mie, Japan
  • Miyagi, Japan
  • Miyazaki, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Nara, Japan
  • Niigata, Japan
  • Numakunai, Japan
  • Okayama, Japan
  • + 17 more on CT.gov